ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced the publication of a study on the St. Jude Medical Biocor™ Stented Tissue Valve that found the valve provided excellent long-term durability as a replacement for the aortic valve in patients 65 years and older. The study, which appears in the October issue of the cardiac journal The Annals of Thoracic Surgery, evaluated the 20-year durability of the Biocor porcine valve in the aortic position.
